WT1-Pulsed DC Cancer Vaccine

Targeting Malignancy at the "Cancer Stem Cell" Level

Personalized Vaccine Innovation:

Terminating the Cycle of Recurrence at its Source.

Conventional cancer treatments often succeed in eliminating the primary tumor mass but may leave behind Cancer Stem Cells (CSCs). These cells are the fundamental drivers of disease recurrence and metastasis. We address this at the root by transforming your immune system into a precision-guided “hunting force.”

Mechanism of Action: "Equipping the Scouts to Train the Hunters"

We harness the potential of Dendritic Cells (DCs) to serve as high-intelligence “Biological Scouts.” By pulsing these cells with highly specific WT1 (Wilms’ Tumor 1) proteins, we encode the cancer’s molecular signature and “present” it to your Killer T-Cells.

This specialized training enables your T-cells to recognize, memorize, and neutralize malignant cells with surgical precision throughout the entire body—effectively identifying and eliminating even the most elusive cancer cells.

Quality Standards You Can Trust at Wincell Research

Original Technology: Authentic, licensed technology from Prof. Dr. Haruo Sugiyama of Osaka University, Japan.
European Patent: The specific WT1 peptide sequences utilized in our process are protected by European patents.
Thai FDA Certified: Our laboratory facility blueprints and operational protocols are authorized by the Thai Food and Drug Administration (FDA), ensuring the highest bio-safety and pharmaceutical-grade standards.

4 Key Advantages of WT1-Pulsed DC Vaccine

Targeted Precision:

Exclusively identifies and neutralizes malignant cells expressing the WT1 protein while sparing healthy surrounding tissues.

Sustained Efficacy:

Stimulates Killer T-Cells to develop a long-term immunological memory, providing an ongoing defense against recurrence.

Safety (Autologous):

Utilizes the patient’s own cells (Autologous cells), significantly reducing the risk of adverse reactions often associated with intensive chemotherapy.